In an era where health-consciousness and looking svelte is more important than ever, cosmetic surgery and cosmetic products have yet to lose favor with consumers and investors.
Endo International PLC (ENDP) shares jumped 47% on Friday after the company announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for collagenase clostridium histolyticum (CCH) for the treatment of cellulite in the buttocks.
According to their website, “Endo International plc is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization.”
The company found that when treated with CCH, there was at least a 2-level composite improvement in cellulite severity in the target buttock at Day 71 as compared to subjects receiving placebo.
“Based on our review of the Phase 3 data, we remain confident in our CCH program for cellulite—a condition that makes many women self-conscious and prompts them to seek treatment options,” said Matthew Davis, M.D., R.Ph., Endo’s Senior Vice President and Chief Medical Officer. “If approved, CCH has the potential to be an important new treatment for cellulite and we are excited to take the next steps in that process.”
Cellulite is an issue that many women are self-conscious about, regardless of the fact that it is extremely common.
“Cellulite is very common; in fact, 93 percent of women have it,” Dendy Engelman, M.D., board-certified dermatologic surgeon at Manhattan Dermatology and Cosmetic Surgery, tells SELF. Other estimates put it at anywhere from 80 to 98 percent. It’s not easy to get an exact estimate because it’s not always something go into the doctor to have treated.
What makes Endo’s treatment unique is there are very few efficacious options currently.
“The Phase 3 results are positive for patients and consistent with previous data that demonstrate CCH has the potential to be a breakthrough treatment for cellulite, a condition that millions of women experience but for which there are currently limited effective treatment options,” said Joely Kaufman-Janette, M.D., a board certified dermatologist at Skin Associates of South Florida, and a CCH clinical trial investigator. “Many of my patients have expressed that they are self-conscious about their cellulite and looking for something to effectively treat it. The fact that CCH is a potential new injectable option to treat cellulite will be very meaningful for my patients and for the aesthetics industry overall.”
Investors interested in Endo and other pharma companies can look at ETFs like the First Trust Nasdaq Pharmaceuticals ETF (FTXH).
For more market trends, visit ETF Trends.
